Acorda Therapeutics, Inc. (ACOR) financial statements (2021 and earlier)

Company profile

Business Address 420 SAW MILL RIVER ROAD
ARDSLEY, NY 10502
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments71126446307159353
Cash and cash equivalents7162294307159153
Short-term investments 64152  200
Restricted cash and investments13131006
Receivables202223815231
Inventory, net of allowances, customer advances and progress billings292529   
Inventory292529   
Prepaid expense151219131316
Assets held-for-sale, not part of disposal group72     
Other current assets2410268
Other undisclosed current assets   384336
Total current assets:221201528442273451
Noncurrent Assets
Operating lease, right-of-use asset1823
Property, plant and equipment714361373440
Intangible assets, net (including goodwill)3674027117171,023614
Goodwill  282287281184
Intangible assets, net (excluding goodwill)367402429431742431
Restricted cash and investments1930    
Deferred costs   223
Other noncurrent assets000165
Deferred tax assets, net   2
Other undisclosed noncurrent assets    4 
Total noncurrent assets:4115997727561,070665
TOTAL ASSETS:6338001,3001,1981,3421,116
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities506512612713280
Accounts payable122649272714
Accrued liabilities38397710010566
Debt6981170
Business combination, contingent consideration, liability225   
Deferred revenue and credits999
Other undisclosed current liabilities171197 1
Total current liabilities:1378614014414891
Noncurrent Liabilities
Long-term debt and lease obligation183241343334324297
Long-term debt, excluding current maturities166218343334324297
Operating lease, liability1723
Liabilities, other than long-term debt68155183155120114
Deferred revenue and credits233242
Deferred income tax liabilities1910
Liability for uncertainty in income taxes 7877 
Other liabilities10121299
Business combination, contingent consideration, liability47781631137264
Derivative instruments and hedges, liabilities159    
Other undisclosed noncurrent liabilities76224486 
Total noncurrent liabilities:257403547534530411
Total liabilities:395489688678678501
Stockholders' equity
Stockholders' equity attributable to parent238311612520664603
Common stock000000
Treasury stock, value(1)(1)(2)(0)(0)(0)
Additional paid in capital1,0089791,005969921813
Accumulated other comprehensive income (loss)(3)(1)37(13)(0)
Accumulated deficit(766)(667)(394)(455)(244)(209)
Total stockholders' equity:238311612520664603
Other undisclosed liabilities and equity     12
TOTAL LIABILITIES AND EQUITY:6338001,3001,1981,3421,116

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues153192471588520493
Revenue, net588520493
Cost of revenue(41)(35)(144)(162)(117)(92)
Cost of goods and services sold(34)(35)(99)(135)(107)(92)
Gross profit:112158327427403400
Operating expenses(190)(530)(289)(660)(439)(459)
Other undisclosed operating income 61   92
Operating income (loss):(78)(312)38(233)(36)34
Nonoperating income (expense)(30)37(18)(19)(6)(15)
Investment income, nonoperating144000
Other nonoperating income (expense)000(1)100
Interest and debt expense5555(22)(19)(17)(15)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(55)(55)22191715
Income (loss) from continuing operations before equity method investments, income taxes:(108)(274)20(252)(42)19
Other undisclosed income from continuing operations before income taxes  0   
Income (loss) from continuing operations before income taxes:(108)(274)20(252)(42)19
Income tax expense (benefit)8113297(8)
Net income (loss):(100)(273)34(223)(36)11
Net income attributable to noncontrolling interest    1 
Net income (loss) available to common stockholders, basic:(100)(273)34(223)(35)11
Interest on convertible debt6     
Net income (loss) available to common stockholders, diluted:(93)(273)34(223)(35)11

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(100)(273)34(223)(36)11
Other comprehensive income (loss)(2)(4)(4)20(13) 
Comprehensive income (loss):(101)(277)30(204)(48)11
Comprehensive income, net of tax, attributable to noncontrolling interest    0 
Other undisclosed comprehensive loss, net of tax, attributable to parent     (0)
Comprehensive income (loss), net of tax, attributable to parent:(101)(277)30(204)(48)11

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: